Abstracts tagged "lung and rheumatoid arthritis"

Abstract Number: 2560 • 2016 ACR/ARHP Annual Meeting
Sputum Antibody to Malondialdehyde-Acetaldehyde Adduct in Subjects with Established Rheumatoid Arthritis
Bryant R. England^1,2, Peter Maloley³, Eric Daubach³, Michael J. Duryee⁴, M. Kristen Demoruelle⁵, Kevin D. Deane⁵, Geoffrey M. Thiele⁶ and Ted R Mikuls⁶, ¹Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²VA Nebraska-Western Iowa, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁶Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Anti-malondialdehyde-acetaldehyde adduct (MAA) antibodies target immunogenic products of oxidative stress, are detected in higher concentration in paired synovial fluid vs serum in RA, and…
Abstract Number: 3017 • 2016 ACR/ARHP Annual Meeting
Elevated Neutrophil Extracellular Trap Levels Correlate with Anti-CCP3-IgG and Anti-CCP3-IgA Levels in the Sputum of Individuals at-Risk for Future Rheumatoid Arthritis
M. Kristen Demoruelle¹, Monica Purmalek², Heather Rothfuss³, Michael Weisman⁴, Lindsay Kelmenson¹, Michael Mahler⁵, Jill M. Norris⁶, Brian Cherrington³, Mariana Kaplan², V. Michael Holers¹ and Kevin D. Deane¹, ¹Rheumatology Division, University of Colorado Denver, Aurora, CO, ²Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Zoology and Physiology, University of Wyoming, Laramie, WY, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Research and Development, Inova Diagnostics, San Diego, CA, ⁶Epidemiology, Colorado School of Public Health, Aurora, CO
Background/Purpose: The initial site of anti-citrullinated protein antibody (ACPA) generation in RA has been proposed to be a mucosal site. We have previously demonstrated ACPA…
Abstract Number: 3019 • 2016 ACR/ARHP Annual Meeting
Sputum Antibodies to Individual Citrullinated Protein/Peptide Antigens Are Elevated in Subjects at-Risk of Future RA and Subjects with Established Disease
Emily Bowers¹, M. Kristen Demoruelle², Michael Weisman³, Jill M. Norris⁴, William H. Robinson⁵, V. Michael Holers² and Kevin D. Deane², ¹Medicine, University of Colorado Denver, Aurora, CO, ²Rheumatology Division, University of Colorado Denver, Aurora, CO, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Epidemiology, Colorado School of Public Health, Aurora, CO, ⁵Stanford University School of Medicine, Stanford, CA
Background/Purpose: Multiple studies demonstrate that ACPAs are elevated in the serum years prior to the onset of seropositive RA during a preclinical period of autoimmunity.…
Abstract Number: 2659 • 2012 ACR/ARHP Annual Meeting
An Expanded Repertoire of Anti-Citrullinated Peptide Antibodies Is Associated with Interstitial Lung Disease in Rheumatoid Arthritis
Jon T. Giles¹, Sonye Danoff², Jeremy Sokolove³, Robert Winchester⁴, Dimitrios A. Pappas⁵, Catriona Cramb⁶, Geoffrey Connors⁷, Stanley S. Siegelman⁸, William H. Robinson⁹ and Joan M. Bathon⁵, ¹Medicine, Columbia University, New York, NY, ²Medicine/Pulmonary, Johns Hopkins School of Medicine, Baltimore, MD, ³Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁴Dept of Medicine & Pathology, Columbia University, New York, NY, ⁵Columbia University, New York, NY, ⁶VA Palo Alto Heatlh Care System and Stanford University, Palo Alto, CA, ⁷Division of Pulmonary and Critical Care Medicine, Yale University, New Haven, CT, ⁸Department of Radiology, Johns Hopkins University, Baltimore, MD, ⁹Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Interstitial lung disease (ILD) is an outcome with high morbidity and mortality in rheumatoid arthritis (RA). Citrullinated proteins are observed in these lung tissues;…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].